Thu, Jul 24, 2014, 3:31 AM EDT - U.S. Markets open in 5 hrs 59 mins

Recent

% | $
Click the to save as a favorite.

Sprint Corporation Message Board

buffet_partner 6 posts  |  Last Activity: Jul 1, 2014 6:00 PM Member since: Jun 28, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Shorts Feel The Pain

    by boyishmn Jul 1, 2014 4:30 PM
    buffet_partner buffet_partner Jul 1, 2014 6:00 PM Flag

    They will lose the shirts. Rally continues.

  • buffet_partner buffet_partner May 14, 2014 9:07 PM Flag

    Security is the issue in the cloud space.
    Believe Rackspace has the security in place
    to withstand the hackers onslaught. Rackspace
    may be among the survivors. They have the
    fundamentals in place.

  • Reply to

    next stop....$46

    by chowyangfat1 May 13, 2014 9:15 AM
    buffet_partner buffet_partner May 14, 2014 1:43 PM Flag

    The growth of Lannett is quite impressive over the last
    year. The shares are still a buy in the near term in the 30s
    range. Price increases last quarter conrtributed to the
    recent decline. Note 19 pending Fda applications.

  • Lannett is a generic drug manfacturer that worth your immediate attention. The
    company reported earnings recently that included a few noteworthy
    fundamental developments. First, they increased prices in the quarter that
    stated that these price increases will lead to a significant benefit in fiscal
    year 2015. The current quarterly results beat the analysts' expectations,
    although the price increaes impacted near term results. A few well
    known insiders have sold shares in the mid 40's. However, several other
    insiders have recently took advantage of the recent weakness and
    bought shares. The shares have declined to attractive levels in the
    mid 30s due to the recent market downturn. The shares represents
    a special situation at the mid 30s range due to its 19 drug applications
    filed with the FDA. Higher beta values in the shares
    should also be noted.

    Happy Investing

  • Lannett is a generic drug manfacturer that worth your immediate attention. The
    company reported earnings recently that included a few noteworthy
    fundamental developments. First, they increased prices in the quarter that
    stated that these price increases will lead to a significant benefit in fiscal
    year 2015. The current quarterly results beat the analysts' expectations,
    although the price increaes impacted near term results. A few well
    known insiders have sold shares in the mid 40's. However, several other
    insiders have recently took advantage of the recent weakness and
    bought shares. The shares have declined to attractive levels in the
    mid 30s due to the recent market downturn. The shares represents
    a special situation at the mid 30s range due to its 19 drug applications
    filed with the FDA. Higher beta values in the shares
    should also be noted.

    Happy investing

  • Lannett is a generic drug manfacturer that worth your immediate attention. The
    company reported earnings recently that included a few noteworthy
    fundamental developments. First, they increased prices in the quarter that
    stated that these price increases will lead to a significant benefit in fiscal
    year 2015. The current quarterly results beat the analysts' expectations,
    although the price increaes impacted near term results. A few well
    known insiders have sold shares in the mid 40's. However, several other
    insiders have recently took advantage of the recent weakness and
    bought shares. The shares have declined to attractive levels in the
    mid 30s due to the recent market downturn. The shares represents
    a special situation at the mid 30s range due to its 19 drug applications
    filed with the FDA. Higher beta values in the shares
    should also be noted.

S
7.68+0.04(+0.52%)Jul 23 4:03 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT